In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates | Zendy

Jeanne Forrester | Zendy; Lisa L. Steed | Zendy; Barbara A. Santevecchi | Zendy; Patrick A. Flume | Zendy; Gloria E Palmer-Long | Zendy; John A. Bosso | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates

Author(s) -

Jeanne Forrester,

Lisa L. Steed,

Barbara A. Santevecchi,

Patrick A. Flume,

Gloria E Palmer-Long,

John A. Bosso

Publication year - 2018

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofy158

Subject(s) - medicine , cystic fibrosis , gram negative bacterial infections , microbiology and biotechnology , gram , gram negative bacteria , in vitro , bacteria , biology , antibiotics , escherichia coli , biochemistry , genetics , gene

Ceftolozane/tazobactam (C/T) was tested and compared against 93 nonfermenting, Gram-negative clinical isolates from cystic fibrosis specimens. Based on current breakpoints for intra-abdominal and urinary tract infections (which may not be appropriate for pulmonary infections), C/T was found to be the most active agent against (95.7% susceptible), followed by piperacillin/tazobactam (89.4% susceptible). For other Gram-negative pathogens included, C/T had varying activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research